Categories
Connect with us on LinkedIn
Where PRO strategy goes wrong: therapeutic area fit, capture frequency, and the implementation gap that takes years to surface
Expert insights on PRO data, regulatory uncertainty, and the implementation gap that kills most ePRO strategies. Watch the...
Beyond the EHR: meeting the FDA’s new real-world evidence standards
The FDA’s December 2025 device guidance and March 2026 ICH M14 adoption raise the bar for RWE programs....
Early-stage biotech’s AI advantage is a window that closes. Sol Babani and Derk Arts on how to use it.
Sol Babani and Derk Arts on why early-stage biotech must build AI-native operations, not retrofit old ones. Decision...
Joel White’s Q4 CRO breakdown: strong bookings, a sell-off that didn’t match, and the disruption gap nobody is talking about
Q4 CRO revenues grew. Bookings accelerated. So why the AI panic? Joel White breaks down what the numbers...
What AI replaces in Phase 2/3 data management, and the edit check question your team hasn’t asked yet
Alison Bishop and Derk Arts on what AI actually replaces in Phase 2/3 data management, with a deep...
Phase 4 and real-world evidence: not a spectrum, a strategic choice
Phase 4 is a post-approval interventional trial that fulfills regulatory commitments. Real-world evidence spans PASS, PAES, HEOR, natural...
ICH E6(R3) is here: what your centralized monitoring strategy needs right now
ICH E6(R3) is in effect. Castor's recap covers centralized monitoring, sponsor accountability, and closing the biotech RBQM gap.
On-site ePRO in Action: A Recap of Castor’s Product Spotlight
Castor’s on-site ePRO adds in-clinic PRO capture to the ePRO/CDMS workflow you already use. Staff use a site...
EQ-5D in European Trials: When Generic QoL Measures Actually Matter
Analysis of 735 FDA drug approvals reveals 0% EQ-5D labeling inclusion, while European HTA bodies demonstrate 18% technology...
ePRO, eCOA 101: Everything You Need to Know About ePRO and eCOA
Electronic Clinical Outcome Assessment (ECOA) and electronic Patient Reported Outcomes (ePRO) represent far more than digital surveys in...
Why eCOA Still Fails in Clinical Trials: Practical Strategies to Fix Baseline Data Problems
Electronic clinical outcome assessments (eCOA) were supposed to solve data quality and amplify the patient voice. Yet missing...
How a 3-Person Team Got to Phase 3 — Without the Overhead
Gameto proves you don’t need a large CRO or a floor of data managers to run complex global...
From Hype to Health: What Sword Health Got Right About Evidence
Sword Health didn’t follow the typical digital health playbook. Instead of rushing to market, they invested early in...
The New Standard in Participant-Centric Trials: What Castor’s 2025 Updates Reveal About the Future of Clinical Research
Explore how Castor’s 2025 updates reduce site burden and boost compliance through scalable, flexible DTP workflows.
Building Biotech: From Science to Scale – Strategic Lessons from the Frontline
Hard truths on scaling biotech: data isn’t enough, CEOs matter, and funding follows story—not science.
Do Patients Really Understand Clinical Trials?
Poor comprehension of informed consent disrupts trials. Here’s how to fix it—with data, tech, and actual patient understanding.
Building a Safer, Smarter Future: A Tiered Approach to AI in Life Sciences
Adopt AI in clinical research with confidence using a risk-based framework that ensures privacy, security, and regulatory alignment.
Why a Life Sciences Museum Matters—And What It Can Teach Us About the Future of Medicine
What a Museum of Medicine can teach us about trials, trust, and how the public sees (or doesn’t...